{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:22:17Z","timestamp":1762885337851,"version":"3.45.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Prolactinomas\/lactotroph pituitary neuroendocrine tumors are ten times less frequent in men than in women and their characteristics are less well known. The latest WHO classification includes them among pituitary tumors with a high risk of recurrence. This study aimed to identify clinical parameters suggesting aggressive prolactinomas. We conducted a retrospective study in three hospitals in Galicia, Spain, including 41 men with prolactinomas. The mean age at diagnosis was 46.5\u2009\u00b1\u200916.2 years. Baseline prolactin levels were a median of 800 ng\/ml, with 95% being macroprolactinomas. Aggressive prolactinomas (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200910) compared to non-aggressive (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200931), had higher rates of visual disturbances (60% vs. 13%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.005) and deficiencies of thyroid-stimulating hormone (70% vs. 13%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.001) and adrenocorticotropic hormone (50% vs. 7%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.006) at diagnosis. Prolactin levels correlated with tumor maximum diameter, more stronger in aggressive cases (\n                    <jats:italic>r<\/jats:italic>\n                    \u2009=\u20090.68;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.047). In our study, a 24% of the prolactinomas were classified as aggressive. We found that prolactinomas in males presented with significantly elevated prolactin levels that correlate strongly with tumor diameter, as well as, visual disturbances and deficiencies of thyroid-stimulating hormone and adrenocorticotropic hormone, should raise suspicion of aggressive lactotroph pituitary neuroendocrine tumors\/prolactinomas.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-23646-z","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:18:43Z","timestamp":1762885123000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aggressive prolactinomas in men are associated with visual disturbances and pituitary hormone deficiencies"],"prefix":"10.1038","volume":"15","author":[{"given":"Everardo J.","family":"D\u00edaz-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"Villar-Taibo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Fern\u00e1ndez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Cotovad-Bellas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Pena-Dubra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Prado-Mora\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Rodr\u00edguez-Carnero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Vargas-Osorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Manuel","family":"Cameselle-Teijeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Bernab\u00e9u","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"23646_CR1","unstructured":"Perry, A., Grossman, A., Lopes, M. B. S., Nishioka, H. & Uccella, S. Lactotroph PitNET\/adenoma. In Endocrine and Neuroendocrine Tumours (5th ed., WHO Classification of Tumours series, vol. 10) Lyon: International Agency for Research on Cancer (2022). Available at: https:\/\/publications.iarc.fr"},{"key":"23646_CR2","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1056\/NEJMcp0912025","volume":"362","author":"A Klibanski","year":"2010","unstructured":"Klibanski, A. Clinical practice. Prolactinomas. N Engl. J. Med. 362, 1219\u20131226 (2010).","journal-title":"N Engl. J. Med."},{"key":"23646_CR3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s11102-016-0723-4","volume":"19","author":"I Shimon","year":"2016","unstructured":"Shimon, I. et al. Giant prolactinomas larger than 60\u00a0mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas. Pituitary 19, 429\u2013436 (2016).","journal-title":"Pituitary"},{"key":"23646_CR4","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn, S. et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement. Nat. Rev. Endocrinol. 19, 722\u2013740 (2023).","journal-title":"Nat. Rev. Endocrinol."},{"key":"23646_CR5","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3389\/fendo.2018.00706","volume":"9","author":"A Wierinckx","year":"2018","unstructured":"Wierinckx, A. et al. Sex-related differences in lactotroph tumor aggressiveness are associated with a specific gene-expression signature and genome instability. Front. Endocrinol. 9, 706 (2018).","journal-title":"Front. Endocrinol."},{"key":"23646_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1159\/000497205","volume":"109","author":"NC Olarescu","year":"2019","unstructured":"Olarescu, N. C. et al. Aggressive and malignant prolactinomas. Neuroendocrinology 109, 57\u201369 (2019).","journal-title":"Neuroendocrinology"},{"key":"23646_CR7","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00401-017-1769-8","volume":"134","author":"MBS Lopes","year":"2017","unstructured":"Lopes, M. B. S. The 2017 world health organization classification of tumours of the pituitary gland: a summary. Acta Neuropathol. 134, 521\u2013535 (2017).","journal-title":"Acta Neuropathol."},{"key":"23646_CR8","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0796","volume":"178","author":"G Raverot","year":"2018","unstructured":"Raverot, G. et al. European society of endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas. Eur. J. Endocrinol. 178, G1\u2013G24 (2018).","journal-title":"Eur. J. Endocrinol."},{"key":"23646_CR9","doi-asserted-by":"publisher","first-page":"1204206","DOI":"10.3389\/fendo.2023.1204206","volume":"14","author":"C Lamas","year":"2023","unstructured":"Lamas, C. et al. Efficacy and safety of Temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain. Front. Endocrinol. 14, 1204206 (2023).","journal-title":"Front. Endocrinol."},{"key":"23646_CR10","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41574-021-00550-w","volume":"17","author":"G Raverot","year":"2021","unstructured":"Raverot, G. et al. Aggressive pituitary tumours and pituitary carcinomas. Nat. Rev. Endocrinol. 17, 671\u2013684 (2021).","journal-title":"Nat. Rev. Endocrinol."},{"key":"23646_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000318494","volume":"38","author":"P Fainstein Day","year":"2010","unstructured":"Fainstein Day, P. et al. Gender differences in macroprolactinomas: study of clinical features, outcome of patients and Ki-67 expression in tumor tissue. Front. Horm. Res. 38, 50\u201358 (2010).","journal-title":"Front. Horm. Res."},{"key":"23646_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","volume":"33","author":"SL Asa","year":"2022","unstructured":"Asa, S. L., Mete, O., Perry, A. & Osamura, R. Y. Overview of the 2022 WHO classification of pituitary tumors. Endocr. Pathol. 33, 6\u201326 (2022).","journal-title":"Endocr. Pathol."},{"key":"23646_CR13","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1750-3639.2012.00599.x","volume":"22","author":"O Mete","year":"2012","unstructured":"Mete, O. & Asa, S. L. Clinicopathological correlations in pituitary adenomas. Brain Pathol. 22, 443\u2013453 (2012).","journal-title":"Brain Pathol."},{"key":"23646_CR14","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1530\/EJE-09-0012","volume":"160","author":"E Delgrange","year":"2009","unstructured":"Delgrange, E., Daems, T., Verhelst, J., Abs, R. & Maiter, D. Characterization of resistance to the prolactin-lowering effects of Cabergoline in macroprolactinomas: a study in 122 patients. Eur. J. Endocrinol. 160, 747\u2013752 (2009).","journal-title":"Eur. J. Endocrinol."},{"key":"23646_CR15","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1210\/jc.2009-1191","volume":"95","author":"G Raverot","year":"2010","unstructured":"Raverot, G. et al. Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J. Clin. Endocrinol. Metab. 95, 1708\u20131716 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"23646_CR16","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11060-013-1270-8","volume":"117","author":"ME Molitch","year":"2014","unstructured":"Molitch, M. E. Management of medically refractory prolactinoma. J. Neurooncol. 117, 421\u2013428 (2014).","journal-title":"J. Neurooncol"},{"key":"23646_CR17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000499382","volume":"109","author":"J Trouillas","year":"2019","unstructured":"Trouillas, J. et al. Clinical, pathological, and molecular factors of aggressiveness in lactotroph tumours. Neuroendocrinology 109, 70\u201376 (2019).","journal-title":"Neuroendocrinology"},{"key":"23646_CR18","first-page":"989","volume":"87","author":"G Di Chiro","year":"1962","unstructured":"Di Chiro, G. & Nelson, K. B. The volume of the Sella turcica. Am. J. Roentgenol. Radium Ther. Nucl. Med. 87, 989\u20131008 (1962).","journal-title":"Am. J. Roentgenol. Radium Ther. Nucl. Med."},{"key":"23646_CR19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed, S. et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 273\u2013288 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"23646_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"23646_CR21","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00701-005-0498-2","volume":"147","author":"E Delgrange","year":"2005","unstructured":"Delgrange, E., Sassolas, G., Perrin, G., Jan, M. & Trouillas, J. Clinical and histological correlations in prolactinomas, with special reference to Bromocriptine resistance. Acta Neurochir. (Wien). 147, 751\u2013757 (2005).","journal-title":"Acta Neurochir. (Wien)"},{"key":"23646_CR22","first-page":"152","volume":"26","author":"B Schaller","year":"2005","unstructured":"Schaller, B. Gender-related differences in prolactinomas: a clinicopathological study. Neuro Endocrinol. Lett. 26, 152\u2013159 (2005).","journal-title":"Neuro Endocrinol. Lett."},{"key":"23646_CR23","doi-asserted-by":"publisher","first-page":"9801","DOI":"10.1038\/s41598-021-89256-7","volume":"11","author":"BM Leca","year":"2021","unstructured":"Leca, B. M. et al. Identification of an optimal prolactin threshold to determine prolactinoma size using receiver operating characteristic analysis. Sci. Rep. 11, 9801 (2021).","journal-title":"Sci. Rep."},{"key":"23646_CR24","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1007\/s11102-018-0898-y","volume":"21","author":"W Liu","year":"2018","unstructured":"Liu, W. et al. Clinical outcomes in male patients with lactotroph adenomas who required pituitary surgery: a retrospective single center study. Pituitary 21, 454\u2013462 (2018).","journal-title":"Pituitary"},{"key":"23646_CR25","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1365-2265.2012.04351.x","volume":"77","author":"P Iglesias","year":"2012","unstructured":"Iglesias, P. et al. Prolactinomas in men: a multicentre and retrospective analysis of treatment outcome. Clin. Endocrinol. 77, 281\u2013287 (2012).","journal-title":"Clin. Endocrinol."},{"key":"23646_CR26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1530\/EJE-06-0646","volume":"156","author":"I Shimon","year":"2007","unstructured":"Shimon, I., Benbassat, C. & Hadani, M. Effectiveness of long-term Cabergoline treatment for giant prolactinoma: study of 12 men. Eur. J. Endocrinol. 156, 225\u2013231 (2007).","journal-title":"Eur. J. Endocrinol."},{"key":"23646_CR27","first-page":"3053","volume":"85","author":"JJ Pinzone","year":"2000","unstructured":"Pinzone, J. J. et al. Primary medical therapy of micro- and macroprolactinomas in men. J. Clin. Endocrinol. Metab. 85, 3053\u20133057 (2000).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"23646_CR28","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1023\/A:1025377816769","volume":"5","author":"L Sibal","year":"2002","unstructured":"Sibal, L. et al. Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function. Pituitary 5, 243\u2013246 (2002).","journal-title":"Pituitary"},{"key":"23646_CR29","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1530\/eje.0.1480325","volume":"148","author":"A Colao","year":"2003","unstructured":"Colao, A. et al. Gender differences in the prevalence, clinical features and response to Cabergoline in hyperprolactinemia. Eur. J. Endocrinol. 148, 325\u2013331 (2003).","journal-title":"Eur. J. Endocrinol."},{"key":"23646_CR30","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3171\/jns.2002.97.2.0299","volume":"97","author":"RK Shrivastava","year":"2002","unstructured":"Shrivastava, R. K., Arginteanu, M. S., King, W. A. & Post, K. D. Giant prolactinomas: clinical management and long-term follow up. J. Neurosurg. 97, 299\u2013306 (2002).","journal-title":"J. Neurosurg."},{"key":"23646_CR31","first-page":"2102","volume":"82","author":"E Delgrange","year":"1997","unstructured":"Delgrange, E., Trouillas, J., Maiter, D., Donckier, J. & Tourniaire, J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J. Clin. Endocrinol. Metab. 82, 2102\u20132107 (1997).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"23646_CR32","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1055\/a-0752-0741","volume":"50","author":"P Iglesias","year":"2018","unstructured":"Iglesias, P. et al. Giant prolactinoma in men: clinical features and therapeutic outcomes. Horm. Metab. Res. 50, 791\u2013796 (2018).","journal-title":"Horm. Metab. Res."},{"key":"23646_CR33","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.4065\/73.11.1046","volume":"73","author":"RD Calle-Rodrigue","year":"1998","unstructured":"Calle-Rodrigue, R. D. et al. Prolactinomas in male and female patients: a comparative clinicopathologic study. Mayo Clin. Proc. 73, 1046\u20131052 (1998).","journal-title":"Mayo Clin. Proc."},{"key":"23646_CR34","doi-asserted-by":"publisher","first-page":"e82619","DOI":"10.1371\/journal.pone.0082619","volume":"8","author":"M Pease","year":"2013","unstructured":"Pease, M., Ling, C., Mack, W. J., Wang, K. & Zada, G. Role of epigenetic modification in tumorigenesis and progression of pituitary adenomas: a systematic review. PLoS One. 8, e82619 (2013).","journal-title":"PLoS One"},{"key":"23646_CR35","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s12022-024-09829-w","volume":"35","author":"M Terry","year":"2024","unstructured":"Terry, M. et al. High-grade progression, sarcomatous transformation, and metastasis of pituitary neuroendocrine neoplasms: the UCSF experience. Endocr. Pathol. 35, 338\u2013348 (2024).","journal-title":"Endocr. Pathol."},{"key":"23646_CR36","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1210\/jc.2009-1191","volume":"95","author":"G Raverot","year":"2010","unstructured":"Raverot, G. et al. Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from 94 patients with long postoperative follow-up. J. Clin. Endocrinol. Metab. 95, 1708\u20131716 (2010).","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23646-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23646-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23646-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:18:45Z","timestamp":1762885125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23646-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23646"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-23646-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"9 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Autonomous Research Ethics Committee of de Santiago-Lugo under number 2024\/373. Patient consent was waived due to the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}}],"article-number":"39497"}}